Last reviewed · How we verify
Oral contraceptives cyclic
Cyclic oral contraceptives prevent pregnancy by suppressing ovulation through combined hormonal inhibition of the hypothalamic-pituitary-ovarian axis.
Cyclic oral contraceptives prevent pregnancy by suppressing ovulation through combined hormonal inhibition of the hypothalamic-pituitary-ovarian axis. Used for Contraception / Prevention of pregnancy, Menstrual cycle regulation, Treatment of acne (secondary indication).
At a glance
| Generic name | Oral contraceptives cyclic |
|---|---|
| Also known as | Yasmin. |
| Sponsor | University of Athens |
| Drug class | Hormonal contraceptive |
| Target | Estrogen receptor, Progesterone receptor |
| Modality | Small molecule |
| Therapeutic area | Contraception / Reproductive Health |
| Phase | FDA-approved |
Mechanism of action
These formulations contain estrogen and progestin in a cyclic dosing pattern, where hormones are taken for 21 days followed by a hormone-free interval. The exogenous hormones inhibit the release of follicle-stimulating hormone (FSH) and luteinizing hormone (LH), preventing follicle development and ovulation. Additionally, they thicken cervical mucus and alter the endometrium to provide multiple contraceptive mechanisms.
Approved indications
- Contraception / prevention of pregnancy
- Menstrual cycle regulation
- Treatment of acne (secondary indication)
Common side effects
- Nausea
- Headache
- Breast tenderness
- Breakthrough bleeding
- Venous thromboembolism
- Hypertension
- Weight gain
Key clinical trials
- Anxiety and Depression in Adolescent PCOS (NA)
- Oral Contraceptive Pills Versus Levonorgestrel-Releasing Intrauterine System for Niche-Related Abnormal Uterine Bleeding (NA)
- The Effect Of Polycystic Ovarian Syndrome Treatment On Ocular Surface.
- Exploring the Modulatory Role of Sex Hormones Along the Neuromechanical Axis in Females
- A Drug-drug Interaction Study to Evaluate the Effects of Pelabresib on the Pharmacokinetics of Repaglinide, Midazolam, and Combined Oral Contraceptive in Patients With Advanced Malignancies (PHASE1)
- Role of Estrogen on Skeletal Outcomes in FHA (PHASE2)
- Study of the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are at Risk for Pregnancy (PHASE3)
- Efficacy of Oral Contraceptive, Progesterone, and Inositol on Menstrual Regulation in PCOS (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |